Navigation Links
The American Society for Microbiology honors Anthony R. Richardson
Date:6/7/2012

Washington, DCJune 6, 2012 Anthony R. Richardson, Ph.D., Assistant Professor, Department of Microbiology & Immunology, University of North Carolina Hill School of Medicine, has been honored with one of two 2012 Merck Irving S. Sigal Memorial Awards. These awards, given annually to two young scientists to recognize and award excellence in basic research in medical microbiology and infectious diseases, are presented in memory of Irving S. Sigal, an instrumental figure in the early discovery of therapies to treat HIV/AIDS. "Richardson is a remarkably imaginative scientist whose work bridges microbial physiology, metabolism, and pathogenesis," states his nominator, William Goldman from the University of North Carolina. "His approach is interdisciplinary and mechanistic, and his work has profound implications for understanding the evolution and emergence of highly virulent pathogens."

Richardson received his B.S. in genetic and bioengineering from Purdue University, and his Ph.D. in microbiology and molecular genetics from Emory University. He completed his postdoctoral fellowship in bacterial physiology and pathogenesis at the University of Washington, where he worked in the laboratory of Ferric Fang, who described Richardson as "extremely curious, interactive, and remarkably well readan exceedingly bright and creative scientist who is poised to make major contributions to the field of bacterial pathogenesis."

Richardson's research has always been focused on the role of basic bacterial physiology in the virulence of important human pathogens. As a graduate student, he investigated the role of DNA repair in modulating immune avoidance in epidemic meningococcal meningitis. His findings showed that the rapid host-to-host spread of Neisseria meningitidis in sub-Saharan Africa during seasonal epidemics selected for strains lacking certain aspects of DNA repair. Given the nature of N. menigitidis, this resulted in bacterial populations with extremely diversified surface immunogenicity facilitating rapid adaptation to new hosts.

As a postdoctoral fellow, Dr. Richardson continued studying bacterial metabolism in the context of its interaction with host innate immunity. He showed that host-production of nitric oxide (NO), a broad-spectrum immune effector, targeted multiple metabolic enzymes inhibiting the growth of pathogenic bacteria. In contrast, he found that the human pathogen Staphylococcus aureus, unlike all other tested bacteria including coagulase negative staphylococci, was able to resist the cytotoxic effects of host NO and thrive in its presence. S. aureus NO-resistance was shown to be essential for full virulence and hinged on the ability of the bacterium to evoke a metabolic state inherently resistant to the effects of this immune radical.

In 2008, Dr. Richardson established his laboratory at the University of North Carolina at Chapel Hill, focusing on the metabolic adaptations of S. aureus to host immunitywork that was soon featured as a Science cover article. Richardson's research studies how the availability of host arginine affects the outcomes of S. aureus infections. While the host converts free arginine to NO in response to inflammatory stimuli, arginine can also be converted to a class of compounds known as polyamines under similar conditions. S. aureus can resist the effects of NO, but for unknown reasons certain species of polyamines are lethal to the pathogen. Dr. Richardson's laboratory studies the battle between the host and S. aureus over the fate of free arginine. Mark Smeltzer, University of Arkansas for Medical Sciences, calls his work "both insightful and scientifically compelling, without exception."

Richardson's late graduate mentor, Igor Stojilijkovic, summarized Richardson to Fang: "He has a big brain, but his heart is even bigger. He is one of those rare individuals who you know will make it in any endeavor he chooses to follow."


'/>"/>

Contact: Garth Hogan
ghogan@asmusa.org
American Society for Microbiology
Source:Eurekalert

Related biology news :

1. News from the October 2008 Journal of the American Dietetic Association
2. American Chemical Societys Weekly PressPac -- Sept. 24, 2008
3. Nanotech and synbio: Americans dont know whats coming
4. American Chemical Societys Weekly PressPac
5. American College of Medical Genetics receives $13.5M NIH contract
6. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
7. American Chemical Society Weekly PressPac Oct. 15, 2008
8. Scientists map soils on an extinct American volcano
9. Indiana University research at American Public Health Association meeting
10. North American environmental commission launches trinational vaquita conservation plan
11. News from the November 2008 Journal of the American Dietetic Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart IOT ... to get under way for the framework, which is designed to reduce the use ... to be transferred eventually to other industries that also require efficient IoT and management ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
(Date:2/16/2017)... Feb. 16, 2017   Biostage, Inc. (Nasdaq: ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, announced today the closing on February 15, 2017 ... of common stock and warrants to purchase 20,000,000 shares ... million. The offering was priced at $0.40 per share ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
Breaking Biology Technology: